1. Prioritize early-stage R&D and platform technologies |
• Invest in basic and translational research, and vaccine platform approaches |
• Improve vaccine platform technologies, including addressing, for example, limitations in storage and distribution |
• Understand vaccine targets and correlates of protection for pandemic pathogens |
2. Bolster pandemic pathogen intelligence |
• Build on existing genomic surveillance systems to include a range of pandemic pathogens |
• Strengthen local surveillance systems and better connect to global surveillance hubs |
• Use a range of data sources to monitor newly emerging infectious diseases |
• Predict new epidemics or emerging pathogen variants using vast data sources |
• Share disease intelligence to enable the development of new medical countermeasures |
3. Optimize and de-risk earlier pandemic interventions |
• Optimize the use of non-pharmaceutical interventions before widespread medical countermeasures are available |
• Stockpile essential medicines, hospital supplies, and treatments for surge capacity |
• Diversify response across preparedness tactics, manufacturers, and product technologies to help mitigate single-source risks |
4. Sustain and leverage manufacturing capacity |
• Sustain “warm base” vaccine manufacturing capacity for use in the next pandemic, including production of vaccines for epidemic or endemic infectious diseases |
• Plan for the expense of new start-up facilities and ongoing investment in infrastructure, operations, and workforce |
• Overcome supply shortages for raw materials to enable rapid vaccine production |
• Consider incorporating surge capacity into manufacturing network planning and operations |
• Promote sustainable procurement policies and health-seeking behaviors to establish routine commercial demand, balanced with appropriate supply capacity |
5. Troubleshoot trade, regulatory, and procurement barriers |
• Troubleshoot trade and regulatory barriers to the distribution of essential products |
• Harmonize global regulatory pathways to enable accelerated time to market for products |
• Establish more equitable but also sustainable agreements between manufacturers, national governments, and multilateral organizations on how to respond in the event of a future pandemic |
• Establish proactive pandemic funding mechanisms and integrated preparedness plans |
6. Leverage the power of partnerships to overcome health system challenges |
• Leverage multisectoral partnerships to solve problems of health systems strengthening, supply chains, financing, and consumer engagement |
• Better understand behaviors leading to vaccine hesitancy and leverage insights to develop strategies aimed at increasing uptake |